ALTSTATION.IO

Gilead Sciences, Inc. (GILD) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$152.21

Change

+1.90%

Market Cap

$188.86B

Avg Volume

7.3M

Company Overview

Gilead Sciences, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing medicines to address unmet medical needs. They offer a range of products, particularly in the areas of HIV, viral hepatitis, and oncology. Key products include Biktarvy and Veklury, among others. Their customer base includes healthcare providers, hospitals, and patients worldwide, particularly in the United States and Europe.

Gilead is a market leader in several therapeutic areas, particularly HIV treatments, where they hold a significant share of the market. Their extensive portfolio, along with ongoing research and development collaborations, gives them a competitive edge. However, they face threats from generic competition and rivals like AbbVie and Merck, which also have strong portfolios in related areas. The rapidly changing landscape of healthcare, especially with the rise of biosimilars, poses additional challenges.

Currently, Gilead is in a phase of strategic pivoting. Although their revenue from HIV products remains robust, they have been refocusing their efforts on oncology and viral hepatitis treatments. Recent milestones include their advances in CAR-T cell therapies and collaborations with various biotech firms to expand their research capabilities. Overall, Gilead aims to leverage its strengths to drive growth in new therapeutic areas while navigating a competitive market.

Key Financials

Market Cap

$188.86B

Revenue

$29.09B

EBITDA

$14.14B

Gross Margin

78.7%

Profit Margin

27.9%

Revenue Growth

3.0%

Total Cash

$8.49B

Total Debt

$24.94B

Free Cash Flow

$8.03B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

23.60

Forward P/E

17.41

Beta

0.39

52-Week High

$152.39

52-Week Low

$93.37

EPS

$6.45

50-Day Avg

$126.97

200-Day Avg

$116.53

Price/Book

8.78

Technical Analysis

Over the past 52 weeks, Gilead Sciences, Inc. (GILD) has exhibited a strong upward trend, gaining approximately 64.2% from a low around $90 to its current price of $152.21. Key support levels can be identified at $100 and $110, where previous price consolidations occurred, while resistance appears at approximately $155 and the recent high of $160. The chart also shows a bullish ascending triangle formation, indicating increasing buying pressure leading up to the latest peak. In recent weeks, momentum has further accelerated, with GILD experiencing sharp upward spikes in price, suggesting a robust buying sentiment and continuation of the upward trend. Currently, GILD’s price sits near the upper end of its 52-week range, which implies strong bullish sentiment at these levels and potential challenges in breaking through resistance zones without some volatility.

Recent News and Developments

Gilead Sciences, Inc

(GILD) has experienced significant positive developments in the past week, marked by upward stock price movements, anticipation of upcoming earnings, positive analyst sentiment, and regulatory progress for its oncology pipeline.

Market Update

Here are 3-5 specific news items:

1. Continued Stock Price Gains in Early February

Gilead Sciences (GILD) stock demonstrated a strong upward trend in the first week of February 2026. On February 6, 2026, the stock closed at $152.09. This followed a 2.15% increase on February 5, closing at $149.37, and a 2.06% increase on February 4, closing at $146.23. The stock has climbed 18.06% in the past month, outperforming the Medical sector and the S&P 500.

Market Sentiment and Analyst Recommendations

Bull Case

Gilead is firing on multiple cylinders right now. The stock is up 18% in a month and 64% over 52 weeks because the market is pricing in real pipeline wins. The Trodelvy combo for triple-negative breast cancer showed positive Phase 3 data in a top-tier journal, and the regulatory decision lands this year. Yescarta for primary CNS lymphoma has a BLA coming in February. Anito-cel for multiple myeloma targets a second-half 2026 launch with an acceptance letter expected this quarter. These aren’t speculative shots — they’re late-stage assets with published efficacy data. The company sits on 8.49 billion in cash against 24.94 billion in debt, which is manageable for a biotech of this scale. At a 23.60 P/E with 3% revenue growth, Gilead trades at a reasonable multiple for a company about to unlock multiple oncology approvals. The analyst consensus is overwhelmingly bullish at 26 buy ratings, and recent price target raises from Truist, Citigroup, and UBS to 145-156 range suggest institutional conviction.

Bear Case

The valuation is already pricing in success. At 152.21, the stock sits near the top of its 52-week range and resistance is heavy at 155-160. If any of these pipeline candidates stumble in the clinic or face unexpected regulatory pushback, this stock has limited upside and significant downside risk. Revenue growth of 3% is anemic for a company with a 188.86 billion market cap. The debt load of 24.94 billion is substantial and limits financial flexibility if cash flow disappoints. The stock has rallied 64% in a year, which means it’s already absorbed a lot of good news. The February 10 earnings report could be an inflection point — if the company guides conservatively or signals pipeline delays, the momentum reverses fast. Biotech is binary, and Gilead is betting heavily on four major approvals. Even one significant setback could trigger a sharp correction.

What to Watch

The February 10 Q4 2025 earnings call is the immediate catalyst. Watch for EPS guidance around 1.87 and revenue guidance near 7.68 billion for the quarter. The company needs to confirm its 2026 pipeline timeline, especially the Yescarta BLA in February and the anito-cel acceptance letter this quarter. If management walks back any launch timelines or raises safety concerns, the thesis cracks. Track the regulatory decisions for Trodelvy as the year progresses — a positive PDUFA decision would validate the Phase 3 data and unlock another revenue stream. Monitor cash flow trends and debt reduction progress. The stock’s behavior around the 155 resistance level matters technically. If it breaks through on volume, the next target is 160-165. If it rolls over, watch for support at 145 and 140. Any analyst downgrades or price target cuts would signal institutional confidence is shifting.

Analyst Consensus

BUY

Based on 26 analyst opinions

Low Target

$103.00

Mean Target

$139.46

High Target

$159.00

Earnings and Financial Data

Sector

Healthcare

Industry

Drug Manufacturers – General

Employees

17,600

Earnings & Dividends

Next Earnings

Feb 10, 2026

EPS (Trailing)

$6.45

Dividend Yield

212.0%

Payout Ratio

48.6%

Frequently Asked Questions

Is Gilead Sciences (GILD) a good stock to buy?

Analysts currently recommend a “BUY” for GILD, with a target price of $139.46, suggesting an upside from the current trading price of $152.21. The forward P/E of 17.41 indicates it is relatively undervalued in terms of earnings expectations.

What is GILD’s price target?

The consensus price target for Gilead Sciences is $139.46. This figure reflects analysts’ positive expectations, despite the stock trading above this level currently.

Does Gilead pay a dividend?

Yes, Gilead Sciences offers a dividend yield of 2.12%. This makes GILD an attractive option for income-focused investors, in addition to its growth potential.

What is the 52-week range for GILD?

GILD’s stock has traded between $93.37 and $152.39 over the past year. This volatility can highlight both the stock’s resilience and the opportunities for investors looking for entry points.

What is GILD’s market capitalization?

Gilead Sciences has a market cap of $188.86 billion. This positions it as a significant player in the healthcare sector, reflecting its financial stability and influence in the drug manufacturing industry.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.